Travere Therapeutics (NASDAQ:TVTX) Issues Earnings Results, Beats Estimates By $0.29 EPS

Travere Therapeutics (NASDAQ:TVTX) announced its quarterly earnings data on Monday. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29, FiscalAI reports. The business had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 28.38%. The firm’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.47) earnings per share.

Here are the key takeaways from Travere Therapeutics’ conference call:

• First FDA approval for Filspari in FSGS — establishes Filspari as the first and only approved medicine for FSGS, expanding the U.S. addressable population (company cites >30,000 FSGS patients and >100,000 across IgAN/FSGS) and underpinning a stated ~$3 billion potential peak sales opportunity.
• Strong commercial momentum with record demand in IgA nephropathy (993 new patient start forms in Q1) and Filspari U.S. revenue of $105.2 million (≈88% YoY growth), plus early signs of faster uptake and initial payer approvals in the FSGS launch.
• Pipeline progress on pegtibatinase — enrollment has restarted in the pivotal Phase III HARMONY study and the first post-restart patient was dosed, with top-line results expected in the second half of 2027 and the program positioned as a potential first disease-modifying therapy for classical HCU (addressable ~7,000–10,000 globally).
• Operating costs and certain non-cash expenses rose meaningfully (R&D $57.1M; SG&A $80.3M; royalty expense $24.8M), the GAAP net loss was $37.1M (non‑GAAP net income $4.1M), and the company disclosed cash, marketable securities and receivables of ≈$352M (cash ≈$264.7M), which investors may watch closely given increased investment for launches and the Phase III program.

Travere Therapeutics Price Performance

Travere Therapeutics stock traded down $0.32 during mid-day trading on Wednesday, reaching $44.49. The company had a trading volume of 1,484,535 shares, compared to its average volume of 2,155,411. The company has a market cap of $4.11 billion, a P/E ratio of -193.73 and a beta of 1.13. The business has a fifty day simple moving average of $32.31 and a 200 day simple moving average of $32.71. The company has a current ratio of 2.74, a quick ratio of 2.70 and a debt-to-equity ratio of 2.71. Travere Therapeutics has a fifty-two week low of $13.88 and a fifty-two week high of $48.61.

Insider Activity at Travere Therapeutics

In other news, Director Roy D. Baynes sold 32,750 shares of Travere Therapeutics stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the transaction, the director owned 37,500 shares in the company, valued at approximately $1,548,375. The trade was a 46.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William E. Rote sold 9,100 shares of Travere Therapeutics stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $39.09, for a total transaction of $355,719.00. Following the transaction, the insider owned 113,987 shares in the company, valued at approximately $4,455,751.83. This trade represents a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 310,852 shares of company stock valued at $11,890,666 in the last quarter. Insiders own 4.44% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently modified their holdings of the business. State Street Corp lifted its holdings in shares of Travere Therapeutics by 47.8% during the fourth quarter. State Street Corp now owns 4,756,666 shares of the company’s stock worth $181,752,000 after purchasing an additional 1,538,827 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Travere Therapeutics by 27.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,784,000 shares of the company’s stock worth $41,203,000 after purchasing an additional 599,102 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Travere Therapeutics by 28.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,246,779 shares of the company’s stock worth $85,849,000 after purchasing an additional 494,665 shares during the period. Rock Springs Capital Management LP lifted its holdings in shares of Travere Therapeutics by 2.1% during the fourth quarter. Rock Springs Capital Management LP now owns 2,210,322 shares of the company’s stock worth $84,456,000 after purchasing an additional 45,549 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock valued at $28,715,000 after buying an additional 1,166,460 shares during the period.

Wall Street Analysts Forecast Growth

TVTX has been the topic of a number of research analyst reports. Wedbush raised their target price on shares of Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday. Citigroup raised their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity Group raised their target price on shares of Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a research report on Tuesday, April 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $47.83.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Wells Fargo raised its price target to $50 and upgraded TVTX to “Overweight,” giving the stock fresh upside from current levels. Wells Fargo Price Target Raise
• Positive Sentiment: TD Cowen lifted its target sharply to $60 and maintained a “Buy” — another bullish analyst action that supports upside expectations tied to Travere’s pipeline and commercial execution. TD Cowen Price Target Raise
• Positive Sentiment: Q1 results showed an EPS beat (reported $0.05 vs. consensus -$0.24) and management highlighted FILSPARI approval in FSGS, strong demand and progress on pegtibatinase — positives for revenue growth and long‑term value if commercial momentum continues. Q1 Results & Corporate Update
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and long‑term EPS runway (FY2027–FY2030 forecasts show multi‑year growth), supporting the bullish thesis despite small model adjustments. HC Wainwright Estimates
• Neutral Sentiment: Investors can review the Q1 earnings call transcript for management commentary on commercial traction and pipeline timelines. Earnings Call Transcript
• Negative Sentiment: Revenue missed expectations ($127.2M reported vs. ~$136.2M consensus) and some outlets flagged a quarterly loss/miss on revenue — a near‑term headwind that likely pressured the stock despite the EPS beat. Revenue Miss Coverage
• Negative Sentiment: HC Wainwright trimmed FY2027–FY2030 EPS estimates slightly (minor cuts across years). While small, these revisions reduce near‑term model momentum and may temper upside expectations. HC Wainwright Estimate Revisions
• Negative Sentiment: Director Roy Baynes sold 9,750 shares under a pre‑arranged 10b5‑1 plan (filed with the SEC); insider sales can be viewed negatively by some investors, even if pre‑planned. SEC Filing: Insider Sale

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.